RxDoctor Payments Data

Brian Anderson, DO

Family Medicine · Moline, ILNPI 1134124191

Payments from drug & device makers

$664in general payments, 2019–2025

Across 28 payments — averaging $23.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$179
  • Optinose US, Inc.$116
  • Novartis$80
  • E.r. Squibb & Sons, L.L.C.$49
  • Takeda Pharmaceuticals U.S.A., Inc.$45
  • Johnson & Johnson$37
  • plus $158 from 7 others

What the payments were for

  • Food & beverage$664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$664 in reported general payments places this provider in the 65th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$63,812
Medicare patients
179
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TradjentaLinagliptin41$32,237
OzempicSemaglutide30$30,376
XareltoRivaroxaban36$25,413
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$24,393
TrulicityDulaglutide20$23,219
JardianceEmpagliflozin32$20,375
JanumetSitagliptin Phos/Metformin Hcl14$20,069
EliquisApixaban21$19,150
MyrbetriqMirabegron18$12,362
Combivent RespimatIpratropium/Albuterol Sulfate18$11,758
Breo ElliptaFluticasone/Vilanterol28$11,071
RybelsusSemaglutide12$10,986
FarxigaDapagliflozin Propanediol19$10,520
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$10,011
Incruse ElliptaUmeclidinium Bromide12$10,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$29$55,47788 claims
Novo NordiskOzempic, Rybelsus$25$41,36242 claims
Johnson & JohnsonXarelto$37$25,41336 claims
AstraZenecaFarxiga, Symbicort$37$16,89739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →